
About Hemera Biosciences
Hemera Biosciences is a Healthcare company based in Medford (United States) founded in 2010. Anti-complement gene therapies for AMD treatment are developed pre-clinically. Hemera Biosciences has raised $3.75 million across 1 funding round. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Hemera Biosciences was founded in 2010 and is based in Medford, United States. Focus is placed on the biotechnology sector, where anti-complement gene-based therapies are developed for dry and wet age-related macular degeneration (AMD). This condition represents the primary cause of blindness in older adults, with no options available for 90 of dry AMD cases. Preclinical models have shown reductions in complement-mediated damage to eye tissues through proprietary recombinant molecules.
- Headquarters Medford, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website hemerabiosciences.com
- Social LinkedIn X
- Total Equity Funding$3.75M (USD)
in 1 rounds
- Latest Funding Round$3.75M (USD), Series A
Apr 2013
Funding Insights of Hemera Biosciences
Hemera Biosciences has successfully raised a total of $3.75M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.75 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.75M
- Total Rounds 1
- Last Round Series A β $3.75M
- First Round $3.75M
(Apr 2013)
All 1 funding rounds of Hemera Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2013 | $3.75M | Series A | β | β | β |
People of Hemera Biosciences
1 people are tracked at Hemera Biosciences (1 in leadership).
| Name | Role | Group |
|---|---|---|
Adam Rogers | Chief Executive Officer and Founder | Leadership |
Complete people profiles for Hemera Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Hemera Biosciences
2 dated milestones of Hemera Biosciences across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Hemera Biosciences is founded.
- Funding First funding round of $3.8M.
Competitors of Hemera Biosciences
Hemera Biosciences has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Hemera Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Hemera Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hemera Biosciences
Complete news archive for Hemera Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemera Biosciences
Hemera Biosciences was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Hemera Biosciences is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.
Hemera Biosciences is a funded company, having raised a total of $3.75M across 1 funding round to date. The company's 1st funding round was a Series A of $3.75M, raised on Apr 2013.
Hemera Biosciences was founded in 2010 and is based in Medford, United States. Focus is placed on the biotechnology sector, where anti-complement gene-based therapies are developed for dry and wet age-related macular degeneration (AMD). This condition represents the primary cause of blindness in older adults, with no options available for 90 of dry AMD cases. Preclinical models have shown reductions in complement-mediated damage to eye tissues through proprietary recombinant molecules.
Hemera Biosciences's top competitors include BridgeBio, Forge Biologics and Insitro.
